The National Cancer Institute (NCI) has partnered with Rockland Immunochemicals to develop, in conjunction with the NCIís Center for Cancer Research (CCR), nearly 100 antibodies involved in signal transduction and cancer research.

The partnership between the CCR and Rockland began in 2005 for the development of rabbit polyclonal antibodies against key phospho and non-phosphoproteins implicated in cancer. A 2011 amendment added the development of mouse monoclonal antibodies to the partnershipís scope. To date Rockland has successfully developed and delivered over 94 antibodies to investigators, releasing the majority of these to market; over 40 additional antibodies are in development. Collaborations are ongoing, and new products are continually being added.

National Cancer Institute
BG 9609 MSC 9760
9609 Medical Center Drive
Bethesda, MD 20892-9760
Phone: 1-800-4-CANCER (1-800-422-6237)

Rockland Immunochemicals Inc.
Gilbertsville, PA 19525
Phone: 800.656.7625
Fax: 610.367.7825

This message has been sent and is copyright protected by Rockland Inc. 2013. All rights reserved.